According to a meta-analysis published in Nature Human Behaviour, the widespread use of digital technology may be associated with lower rates of cognitive decline in people over the age of 50. The results of the study — which analysed 57 studies involving more than 400,000 people with an average age of 69 — seem to contradict the hypothesis that the daily use of technology weakens cognitive ability.
While some studies have suggested that having a mother with Alzheimer's may increase the risk of developing the disease, a new study reveals that having a father with the disease may be related to a greater spread of tau protein in the brain, which is a sign of the disease. The study, published in Neurology, does not prove that having a father with Alzheimer's causes these brain changes; it only shows an association.
An international team with Spanish participation has analysed the usefulness of a blood biomarker - the p-tau217 protein - for detecting Alzheimer's disease in 1,767 patients. According to the authors, who publish the results in the journal Nature Medicine, the test has detected the disease with high reliability in four hospital cohorts, as well as in a primary care cohort. They add that it is an assay that can be easily implemented in clinical laboratories and is already routinely used in some centres in Spain.
An American team has developed a ‘smart’ computer keyboard that could be used for the early diagnosis of Parkinson's disease. The prototype is a flexible device, linked to a mobile application, whose keys detect slight variations in the pressure applied by the user, allowing for the quantitative analysis of motor symptoms. The study, published in Science Advances, presents the validation of the keyboard with three people with Parkinson's.
A study published in Nature magazine analysed the medical records of elderly Welsh men and women and discovered that those who had been vaccinated against shingles were 20% less likely to develop dementia in the following seven years. This effect was greater in women. The findings support the theory that viruses that affect the nervous system can increase the risk of dementia.
EMA’s human medicines committee has recommended not authorising the marketing of Kisunla (donanemab), a drug intended for the treatment of early-stage Alzheimer's disease. The committee considered that the benefits of this drug were not great enough to outweigh the risk of potentially fatal events. In recent years, several patients have died due to microbleeds in the brain.
The DIAN-TU platform is an initiative to test Alzheimer's disease treatments early, by recruiting people with a mutation that leads to developing the disease in the future. One of the trials with the anti-amyloid drug gantenerumab ended without reaching the targets. However, a continuation of the study in 73 patients suggests - for the first time, according to the authors - that long-term, high-dose treatment given some time before symptoms develop could delay the onset of the disease. The results are published in the journal The Lancet Neurology.
Discovered years ago, PINK1 is a protein directly linked to Parkinson's disease, but it was not known what it looks like, how it binds to the surface of damaged mitochondria or how it is activated. A study published this week in Science has for the first time determined the structure of this protein. The authors suggest that this new information could help in finding new treatments.
Epstein-Barr virus infection appears to be a necessary condition for developing multiple sclerosis, but the specific mechanisms that cause it in some people are not known. An international study of more than 1,300 people, including 650 patients, has found that elevated production of certain antibodies increases the risk of developing the disease. These antibodies target a specific protein in the virus, but can in turn act in a cross-species manner and damage other similar proteins in the nervous system. The results are published in the journal PNAS.
In 2050 there will be 25.2 million people with Parkinson's disease worldwide, which represents an increase of 112% from 2021, largely due to the ageing of the population, according to a modelling study published by The BMJ. The number of people living with this disease – prevalence across all ages – per 100,000 inhabitants is expected to increase by 76% – and by 55% when age differences are corrected.